Literature DB >> 26822978

Can tumor cells proliferate without ERK5?

Emanuele Giurisato1,2, Cathy Tournier1.   

Abstract

Entities:  

Keywords:  BIX02189; ERK1/2; ERK5; MEK5; RAF; RAS; colon cancer; selumetinib

Mesh：

Substances：

Year:  2016        PMID： 26822978      PMCID： PMC4845921          DOI： 10.1080/15384101.2016.1143272

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control.

Authors:  J M English; G Pearson; T Hockenberry; L Shivakumar; M A White; M H Cobb
Journal:  J Biol Chem       Date:  1999-10-29       Impact factor: 5.157

Review 2.  ERK5: structure, regulation and function.

Authors:  Gopika N Nithianandarajah-Jones; Bettina Wilm; Christopher E P Goldring; Jürgen Müller; Michael J Cross
Journal:  Cell Signal       Date:  2012-07-16       Impact factor: 4.315

3.  Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis.

Authors:  Masaaki Hayashi; Colleen Fearns; Brian Eliceiri; Young Yang; Jiing-Dwan Lee
Journal:  Cancer Res       Date:  2005-09-01       Impact factor: 12.701

4.  Pharmacological inhibition of BMK1 suppresses tumor growth through promyelocytic leukemia protein.

Authors:  Qingkai Yang; Xianming Deng; Bingwen Lu; Michael Cameron; Colleen Fearns; Matthew P Patricelli; John R Yates; Nathanael S Gray; Jiing-Dwan Lee
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

5.  ERK5 is a critical mediator of inflammation-driven cancer.

Authors:  Katherine G Finegan; Diana Perez-Madrigal; James R Hitchin; Clare C Davies; Allan M Jordan; Cathy Tournier
Journal:  Cancer Res       Date:  2015-02-03       Impact factor: 12.701

Review 6.  ERK5 and its role in tumour development.

Authors:  Pamela A Lochhead; Rebecca Gilley; Simon J Cook
Journal:  Biochem Soc Trans       Date:  2012-02       Impact factor: 5.407

7.  Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation.

Authors:  Pamela A Lochhead; Jonathan Clark; Lan-Zhen Wang; Lesley Gilmour; Matthew Squires; Rebecca Gilley; Caroline Foxton; David R Newell; Stephen R Wedge; Simon J Cook
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534
  7 in total
  1 in total

Review 1.  Clinical Significance and Regulation of ERK5 Expression and Function in Cancer.

Authors:  Matilde Monti; Jacopo Celli; Francesco Missale; Francesca Cersosimo; Mariapia Russo; Elisa Belloni; Anna Di Matteo; Silvia Lonardi; William Vermi; Claudia Ghigna; Emanuele Giurisato
Journal:  Cancers (Basel)       Date:  2022-01-11       Impact factor: 6.639
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.